
Martin Bergstrand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2535801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetic modeling and simulation support for age―and weightâ€adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Journal of Thrombosis and Haemostasis, 2021, 19, 1259-1270.	1.9	12
2	Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. Malaria Journal, 2018, 17, 126.	0.8	15
3	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 603-612.	1.3	12
4	In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status. Pharmaceutical Research, 2017, 34, 847-859.	1.7	12
5	Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	16
6	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. AAPS Journal, 2017, 19, 1842-1854.	2.2	12
7	Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 416-424.	0.3	11
8	A strategy for residual error modeling incorporating scedasticity of variance and distribution shape. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 137-151.	0.8	22
9	Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions. Pharmaceutical Research, 2016, 33, 751-762.	1.7	13
10	Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Science Translational Medicine, 2014, 6, 260ra147.	5.8	18
11	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	1.9	263
12	External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. AAPS Journal, 2013, 15, 308-315.	2.2	2
13	Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy. Antimicrobial Agents and Chemotherapy, 2012, 56, 5764-5773.	1.4	44
14	Population Pharmacokinetics of Busulfan in Children–Response. Clinical Cancer Research, 2012, 18, 2717-2718.	3.2	1
15	A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model. AAPS Journal, 2012, 14, 155-163.	2.2	25
16	Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models. AAPS Journal, 2012, 14, 176-186.	2.2	39
17	A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations. Pharmaceutical Research, 2012, 29, 695-706.	1.7	18
18	A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations. Pharmaceutical Research, 2012, 29, 574-584.	1.7	16

#	Article	IF	CITATIONS
19	Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS Journal, 2011, 13, 143-151.	2.2	1,057
20	Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation Clearance. Therapeutic Drug Monitoring, 2011, 33, 663-672.	1.0	37
21	Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children. Clinical Cancer Research, 2011, 17, 6867-6877.	3.2	54
22	Handling Data Below the Limit of Quantification in Mixed Effect Models. AAPS Journal, 2009, 11, 371-380.	2.2	249